Bioeel in 2021 posted turnover worth RON562 million (EUR114.2 million), up 18% from the previous year.
“Estimates for 2022, in the current context, are cautious and in line with the market growth trend, put at 7-8% from 2021,” Bioeel officials told ZF Transilvania.
Bioeel is a privately held company active since 1992 through drug and cosmetics production.
The company expanded beyond production and has come to import and distribute pharmaceutical products for several local and international pharma companies. Bioeel has its own distribution network and its own brand.
For 2022, Bioeel has budgeted RON3.2 million investments in technology, security, equipment and machinery. Bioeel ended 2021 with 233 employees at group level and at end-January 2022 had already reached 255 people.
(English version by Catalina Apostoiu)